Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04772287 | Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008) | PHASE3 | NOT YET_RECRUITING | 341 | — | — | Mar 31, 2021 | Dec 30, 2027 | Feb 26, 2021 | - | — |
It refers to the time from radical surgery to relapse or death of a participant due to disease progression. In the case of a patient who still survives at the time of analysis, the latest evaluation date will be used for interpolation (censoring).
| Arm | Type | Description |
|---|---|---|
| Toripalimab | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Toripalimab | DRUG | Toripalimab: 240mg, IV, q3w, 4 cycles in total; Platinum-containing dual-drug chemotherapy: The specific dose is based on the standard of the selected protocol, IV, q3w, a total of 4 cycles. |
| Toripalimab mimetic (placebo) | DRUG | Placebo: 240mg, IV, q3w, 4 cycles in total; Platinum-containing dual-drug chemotherapy: The specific dose is based on the standard of the selected protocol, IV, q3w, a total of 4 cycles. |
Inclusion Criteria: 1. Volunteer to participate in this clinical study, understand the research procedures and be able to sign written informed consent. 2. Age ≥18 years old. 3. Histological diagnosis of primary non-small cell lung cancer (NSCLC). 4. An MRI or CT scan of the brain must be performed...